ArticleNews reportPHN-05472026-11-02 02:40 CT

Sun Pharma slides nearly 2% as Ilumya concerns weigh on analyst estimates

Source · TradingView

TLDR

Sun Pharmaceutical Industries shares fell 1.81% to ₹1,745.60 following Q2FY27 results, as slower Ilumya growth and a ₹12.7 billion exceptional charge weighed on sentiment. Analysts issued mixed assessments, with Elara Securities citing semaglutide traction and branded generics as offsets to specialty weakness.

01—Key points

01Revenue rose 11.8% year-on-year to ₹161 billion, while global specialty sales grew 6.9%.
02Bank of America cut its earnings estimate, citing higher R&D spending and specialty concentration risks.
03Elara upgraded the stock to Buy, citing strong branded generics and semaglutide traction.

Why it matters Editorial

The report identifies semaglutide traction as one analyst’s reason for optimism, but provides no detailed sales figures for it.

Read the original at TradingView↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.